Pelthos Therapeutics Inc. Formerly Channel Therapeutics Corporation, Chromocell Therapeutics Corporation
Pelthos Therapeutics Inc. is listed today as Pelthos Therapeutics Inc. : market value, financials and filings are on its company page.
Funding rounds 0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
Funding rounds of Pelthos Therapeutics Inc. Month Raised Raise Size Investors Sold Filing Oct 2026 $58 M Private placement after listing $50 to $250 million 7
Pelthos Therapeutics Inc.: Private sale, Oct 2026 × Investors in this round 7 investors had bought by the notice of Nov 16, 2026: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Pelthos Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $58 M of $58 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice John M. Gay · Executive Officer · Chief Financial Officer, Treasurer and Secretary Peter Greenleaf · Executive Officer, Director · Chairman Sai Rangarao · Executive Officer · Chief Commercial Officer Scott Plesha · Executive Officer, Director · Chief Executive Officer Andrew Einhorn · Director Ezra Friedberg · Director Matthew Pauls · Director Richard Baxter · Director Richard Malamut · Director Todd Davis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John M. Gay, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Nov 16, 2026. Read the notice at the SEC .
equity, options SEC Nov 2025 $18 M Private placement after listing $10 to $50 million 8
Pelthos Therapeutics Inc.: Private sale, Nov 2025 × Investors in this round 8 investors had bought by the notice of Nov 19, 2025: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Pelthos Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $18 M of $18 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them, other: Senior secured convertible notes, which are convertible into shares of the Company's common stock, par value $0.0001 per share. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Francis Knuettel II · Executive Officer · Chief Financial Officer Sai Rangarao · Executive Officer · Chief Commercial Officer Scott Plesha · Executive Officer, Director · Chief Executive Officer Ezra Friedberg · Director Matthew Pauls · Director Peter Greenleaf · Director Richard Baxter · Director Richard Malamut · Director Todd Davis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Francis Knuettel II, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Nov 19, 2025. Read the notice at the SEC .
options SEC Jul 2025 $50 M Private placement after listing $50 to $250 million 13
Pelthos Therapeutics Inc.: Private sale, Jul 2025 × Investors in this round 13 investors had bought by the notice of Jul 10, 2025: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Pelthos Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Convertible Preferred Stock, par value $0.0001 per share, convertible into shares of the Company's common stock, par value $0.0001 per share. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Francis Knuettel II · Executive Officer · Chief Financial Officer, Treasurer and Secretary Sai Rangarao · Executive Officer · Chief Commercial Officer Scott Plesha · Executive Officer, Director · Chief Executive Officer and President Ezra Friedberg · Director Matthew Pauls · Director Peter Greenleaf · Director Richard Baxter · Director Richard Malamut · Director Todd Davis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents a purchase price consisting of (i) the conversion of approximately $0.1M payable under an outstanding convertible note issued by the Company and (ii) an aggregate of $33,815,252 in shares of Series A Preferred Stock and Common Stock.”Signed by Francis Knuettel II, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Jul 10, 2025. Read the notice at the SEC .
equity, options SEC
Source: SEC Form D . Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Pelthos Therapeutics Inc., its revenue in fiscal 2025 came from these product and service lines: Net product revenues $16.21 million (96%), License and collaboration revenues $590,000 (4%).
Annual report (SEC XBRL) · Dec 2025
Pelthos Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).
SEC Form D · Nov 2026
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2026
No products or services of Pelthos Therapeutics Inc. are on record.
1 named in official filings. Open an investor to see everything it has backed.
Investors in Pelthos Therapeutics Inc. Investor Kind Amount Round Role Source Ligand Pharmaceuticals Inc Company not stated not stated Held Series A preferred stock, 10% owner (Form 3, 2025) SEC Form 3
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today Institutions holding Pelthos Therapeutics Inc. shares, as of Sep 30, 2026.
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page .
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Pelthos Therapeutics Inc. Name Role Named in John M. Gay Chief Financial Officer, Treasurer and Secretary Nov 2026 Peter Greenleaf Chairman Nov 2026 Sai Rangarao Chief Commercial Officer Nov 2026 Scott Plesha Chief Executive Officer Nov 2026 Francis Knuettel II Chief Financial Officer Nov 2025 Andrew Einhorn Director Nov 2026 Ezra Friedberg Director Nov 2026 Matthew Pauls Director Nov 2026 Peter Greenleaf Chairman Nov 2026 Richard Baxter Director Nov 2026 Richard Malamut Director Nov 2026 Scott Plesha Chief Executive Officer Nov 2026 Todd Davis Director Nov 2026
Went public since 2023. Its SEC number is that of a company listed on a stock exchange.